Developing the Breast Cancer Self-Efficacy Scale for Partners (BCSES-P)
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 25
- 试验地点
- 1
- 主要终点
- Fear of Cancer Progression and Recurrence (FCR7)
研究概览
简要总结
The concept of self-efficacy is a major predictor of physical, psychological, social and overall quality of life (QoL) among breast cancer survivors (BCS). Because survivor and partner outcomes are often linked, it is reasonable to hypothesize that self-efficacy is an important predictor of physical, psychological, social and overall QoL in partners as well. However, this hypothesis has yet to be tested, in part because no scale exists to measure cancer-related self-efficacy in partners. Development and psychometric testing of such a scale is a critical first step in developing a theoretical model predicting QoL in this population. Partners of BCS often report lower QoL compared to partners of healthy women, making them an important focus of research. During the award period, the applicant will follow standard instrument development procedures to develop the Breast Cancer Self-Efficacy Scale for Partners (BCSES-P) and test the scale's psychometric properties using a large and diverse sample of partners of breast cancer survivors.
详细描述
Compared to partners of healthy women, partners of breast cancer survivors (BCS) are at an increased risk of affective disorders, including depression and anxiety;1 are more likely to report antidepressant use for up to 14 years after their partners' diagnosis and treatment; and more likely to report lower vitality and more quality of life deficits.2 Despite these significant negative health outcomes, partners of BCS have rarely been studied and factors that contribute to their QoL have not been identified. Because these factors would serve as targets of interventions to improve well-being in this population, this represents a significant gap.
In BCS, self-efficacy, one's belief in one's ability to handle a situation, is positively related to quality of life (QoL) and has a protective effect against psychological morbidity.5 In this population, self-efficacy is an important predictor of a wide range of outcomes including: attention function, anxiety, depression, marital satisfaction, sexuality, self-esteem,6 fear of recurrence,7 subjective memory impairment, physical activity,8 health behaviors,9 and satisfaction with healthcare provider communication.7 Given the importance of self-efficacy in predicting QoL and health outcomes of BCS, it is reasonable to hypothesize that self-efficacy in partners is associated with these factors as well. However, without a scale to measure partners' cancer-related self-efficacy, this hypothesis cannot be tested and our ability to build theoretically based interventions to fully address partners' QoL is severely limited.
Previous studies measuring partners' self-efficacy have utilized generic self-efficacy scales that fail to address the unique challenges and experiences that partners of BCS face. For other types of cancer (e.g., prostate), partner self-efficacy scales have been adapted from survivors. Because existing scales do not target the unique experience of being partnered with a BCS, a valid and reliable scale to measure self-efficacy in this population is needed.
Furthermore, a theoretical framework for testing construct validity is needed. Ferrell and Dow's Quality of Life Model will provide the theoretical foundation for the Breast Cancer Self-Efficacy Scale for Partners (BCSES-P).
Therefore, the purpose of this study is to develop and psychometrically test the Breast Cancer Self-Efficacy Scale for Partners (BCSES-P). The specific aims are as follows:
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Identifies as a partner, significant other, or spouse of an individual diagnosed with non-metastatic breast cancer
- •Is 18 years of age or over
- •Is able and willing to attend a focus group, individual interview, or complete an online survey
- •Is able to access the internet
- •Is able to carry on normal everyday conversation
排除标准
- •· Partners who have separated or divorced since survivors' diagnosis
结局指标
主要结局
Fear of Cancer Progression and Recurrence (FCR7)
时间窗: Day 1
7-item scale assessing concerns that the cancer will progress or return, previously tested in samples of breast cancer survivor caregivers/spouses, Cronbach alpha=.91.
次要结局
- PROMIS Depression Short Form (8 items)(Day 1)
研究者
Andrea Alise Cohee
Assistant Professor
Indiana University
